Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
2257.HK
STRONG SELLREMOVESirnaomics Ltd. · Healthcare · United States · $82M · Avg Vol: $96K/d
Sirnaomics is an unprofitable clinical-stage biopharma company that does not possess the established commercial moat of a quality compounder.
COMPANY DESCRIPTION
Sirnaomics Ltd. is a clinical-stage biopharmaceutical company focused on discovering and developing RNA interference (RNAi) therapeutics for oncology and rare diseases. Its proprietary polypeptide nanoparticle (PNP) technology enables targeted drug delivery, representing a unique competitive advantage in the rapidly evolving RNA therapeutics space. Sirnaomics is a pioneering company in the RNAi therapeutic field, with several drug candidates in various clinical trial phases.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|---|
| Revenue | — | 0 | 0 | 226,912 | 0 | — |
| EPS | -1.82 | -0.15 | -0.13 | -0.08 | — | — |
| Shares | — | 88M | 88M | 105M | 107M | +21.9% |
| Debt | 0 | 1M | 1M | 1M | 1M | -4.7% |
| Equity | — | 16M | 5M | -214,405 | -1M | -67.1% |
| Op CF | — | -11M | -9M | -3M | -1M | — |
| Inv CF | — | -4M | -682,778 | 272,856 | 2,935 | — |
| Fin CF | — | 2M | -715,449 | 742,377 | 1M | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 2257.HK are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| 2257.HK | Sirnaomics Ltd.(you) | $82M | 7 | STRONG SELL |
| ANIX | Anixa Biosciences, Inc. | $91M | 7 | STRONG SELL |
| AARD | Aardvark Therapeutics, Inc. | $92M | 7 | STRONG SELL |
| GOSS | Gossamer Bio, Inc. | $79M | 9 | STRONG SELL |
| ATYR | aTyr Pharma, Inc. | $82M | 3 | STRONG SELL |
| GANX | Gain Therapeutics, Inc. | $86M | 3 | STRONG SELL |
| FLNA | Filana Therapeutics, Inc. | $75M | 11 | STRONG SELL |
| PEPG | PepGen Inc. | $104M | 7 | STRONG SELL |
| SGMO | Sangamo Therapeutics, Inc. | $87M | 3 | STRONG SELL |
| CGTX | Cognition Therapeutics, Inc. | $107M | 9 | STRONG SELL |
Peer medians: ROE -22.6% · P/E 25.3x · Gross margin 44.3%